Back to Research Hub
Taysha Gene Therapies, Inc.
TSHA
$5.36-0.07 (-1.29%)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
StreetsValue research for Taysha Gene Therapies, Inc. (TSHA)
Members get the full report for Taysha Gene Therapies, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.